EA200001192A1 - Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона - Google Patents
Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсонаInfo
- Publication number
- EA200001192A1 EA200001192A1 EA200001192A EA200001192A EA200001192A1 EA 200001192 A1 EA200001192 A1 EA 200001192A1 EA 200001192 A EA200001192 A EA 200001192A EA 200001192 A EA200001192 A EA 200001192A EA 200001192 A1 EA200001192 A1 EA 200001192A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cabergoline
- pramipexol
- disease
- treat
- pramipexole
- Prior art date
Links
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title abstract 5
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 abstract 4
- 229960004596 cabergoline Drugs 0.000 abstract 4
- 229960003089 pramipexole Drugs 0.000 abstract 3
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Настоящее изобретение раскрывает новое применение и способы лечения с привлечением каберголина, прамипексола и новых комбинаций каберголина и прамипексола, применяемых для лечения пациентов. В настоящем документе раскрывается применение каберголина или прамипексола для лечения ПСП и ПСА. Также раскрывается комбинированное лечение каберголином и прамипексолом, вводимым одновременно пациенту, который в этом нуждается, для лечения различных заболеваний центральной нервной системы и, в частности, для лечения болезни Паркинсона (БП), но также для лечения ПСП и ПСА.Отчет о международном поиске был опубликован 2000.04.13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8561998P | 1998-05-15 | 1998-05-15 | |
| US8794398P | 1998-06-04 | 1998-06-04 | |
| PCT/US1999/007024 WO1999059563A2 (en) | 1998-05-15 | 1999-05-07 | Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200001192A1 true EA200001192A1 (ru) | 2001-04-23 |
| EA004474B1 EA004474B1 (ru) | 2004-04-29 |
Family
ID=26772918
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200300125A EA200300125A1 (ru) | 1998-05-15 | 1999-05-07 | Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
| EA200300124A EA200300124A1 (ru) | 1998-05-15 | 1999-05-07 | Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
| EA200001192A EA004474B1 (ru) | 1998-05-15 | 1999-05-07 | Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола |
| EA200200955A EA200200955A1 (ru) | 1998-05-15 | 1999-05-07 | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200300125A EA200300125A1 (ru) | 1998-05-15 | 1999-05-07 | Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
| EA200300124A EA200300124A1 (ru) | 1998-05-15 | 1999-05-07 | Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200200955A EA200200955A1 (ru) | 1998-05-15 | 1999-05-07 | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6503920B1 (ru) |
| EP (1) | EP1076559B1 (ru) |
| JP (1) | JP2002515425A (ru) |
| KR (3) | KR20060056417A (ru) |
| CN (1) | CN1301159A (ru) |
| AT (1) | ATE310517T1 (ru) |
| AU (1) | AU748629B2 (ru) |
| BR (1) | BR9909917A (ru) |
| CA (1) | CA2327299A1 (ru) |
| DE (1) | DE69928521T2 (ru) |
| DK (1) | DK1076559T3 (ru) |
| EA (4) | EA200300125A1 (ru) |
| ES (1) | ES2251191T3 (ru) |
| HU (1) | HUP0101803A3 (ru) |
| IL (1) | IL139682A0 (ru) |
| NO (1) | NO20005757L (ru) |
| NZ (2) | NZ508184A (ru) |
| PL (1) | PL344574A1 (ru) |
| SG (1) | SG121745A1 (ru) |
| SK (1) | SK16272000A3 (ru) |
| TR (1) | TR200003356T2 (ru) |
| WO (1) | WO1999059563A2 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007309D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| AR040682A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| GB0221513D0 (en) * | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
| EP1789021B2 (en) | 2004-08-13 | 2014-10-08 | Boehringer Ingelheim International GmbH | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| EP1778201B1 (en) | 2004-08-13 | 2014-07-16 | Boehringer Ingelheim International GmbH | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| PL232974B1 (pl) * | 2015-12-09 | 2019-08-30 | Ofta Spolka Z Ograniczona Odpowiedzialnoscia | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| EP0664705B1 (en) * | 1993-08-18 | 2000-10-04 | Alcon Laboratories, Inc. | Compositions of ergoline derivatives for the treatment of glaucoma |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
| FR2728374A1 (fr) * | 1994-12-15 | 1996-06-21 | Aerospatiale | Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol |
-
1999
- 1999-05-07 CA CA002327299A patent/CA2327299A1/en not_active Abandoned
- 1999-05-07 PL PL99344574A patent/PL344574A1/xx not_active IP Right Cessation
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/ja active Pending
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/hu unknown
- 1999-05-07 IL IL13968299A patent/IL139682A0/xx unknown
- 1999-05-07 EA EA200300125A patent/EA200300125A1/ru unknown
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/pt not_active Application Discontinuation
- 1999-05-07 CN CN99805219A patent/CN1301159A/zh active Pending
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/xx unknown
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/ko not_active Application Discontinuation
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/en active IP Right Grant
- 1999-05-07 EA EA200300124A patent/EA200300124A1/ru unknown
- 1999-05-07 DE DE69928521T patent/DE69928521T2/de not_active Expired - Fee Related
- 1999-05-07 EA EA200001192A patent/EA004474B1/ru not_active IP Right Cessation
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 AT AT99919772T patent/ATE310517T1/de not_active IP Right Cessation
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/ko not_active Application Discontinuation
- 1999-05-07 EA EA200200955A patent/EA200200955A1/ru unknown
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/ko not_active Application Discontinuation
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/sk unknown
- 1999-05-07 DK DK99919772T patent/DK1076559T3/da active
- 1999-05-07 EP EP99919772A patent/EP1076559B1/en not_active Expired - Lifetime
- 1999-05-07 ES ES99919772T patent/ES2251191T3/es not_active Expired - Lifetime
-
2000
- 2000-11-14 NO NO20005757A patent/NO20005757L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
| DK1137762T3 (da) | Behandling af Pompes sygdom | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| EA200001192A1 (ru) | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
| ZA9810444B (en) | Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
| WO2002002518A3 (en) | Compounds to treat alzheimer's disease | |
| WO2002002520A8 (en) | Compounds to treat alzheimer's disease | |
| WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| IL157363A0 (en) | Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands | |
| MY124071A (en) | Treatment of viral disease in swine | |
| HUP0001913A2 (hu) | Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására | |
| HUP9701606A2 (hu) | Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására | |
| RU2147218C1 (ru) | Способ лечения вибрационной болезни | |
| MX9503363A (es) | N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1. | |
| EA199800941A1 (ru) | Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона | |
| RU2000104538A (ru) | Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита | |
| RU2000106699A (ru) | Способ лечения заболеваний методом настройки биоритмов организма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |